ライフサイエンスコーパス: serious

1 e St-Cp group (63 versus 173; P<0.001), both serious (11 versus 46; P<0.001) and nonserious (52 versu

2 Delirium is a serious acute neurocognitive condition frequently occurr

3 aced with such a wide variety of potentially serious adverse consequences, prescribers need to evalua

4 (GC)-induced ocular hypertension (OHT) is a serious adverse effect of prolonged GC therapy that can

5 hrough which clozapine may act to cause this serious adverse effect.

6 Like alcohol and tobacco, cannabis can have serious adverse effects on health, and some people have

7 placebo with mandatory dose escalation if no serious adverse effects were experienced.

8 t (29 [13%] of 223 vs 141 [64%] of 219) or a serious adverse event (11 [5%] of 223 vs 63 [29%] of 219

9 Incident decompensation was the most common serious adverse event (7% overall).

10 One serious adverse event (transient atrial fibrillation) oc

11 One serious adverse event during deferred treatment (interst

12 The most common serious adverse event in the active surveillance group w

13 5%) and 22 (8%) patients had an on-treatment serious adverse event in the mepolizumab and placebo gro

14 The most common serious adverse event in the vascular-targeted photodyna

15 No serious adverse event occurred in more than one particip

16 quartile range, 20-30 mo), no patients had a serious adverse event or relapse of vasculitis.

17 ety and regulatory affairs personnel to meet serious adverse event reporting requirements.

18 b and 54 (20%) of 265 assigned placebo had a serious adverse event that was judged by the investigato

19 At least one serious adverse event was reported in 65 (41%) of 157 pa

20 2.90, p = 0.6176; 1 death was reported as a serious adverse event).

21 l adhesions with obstruction as a severe and serious adverse event, which was considered as unrelated

22 arthropathy in one participant was the only serious adverse event.

23 lled studies reported low rates of death and serious adverse events (0% to 1.25%) in nontransported p

24 17 serious adverse events (3%) were reported during the stu

25 of 78 patients vs 81 [99%] of 82 patients), serious adverse events (36 [46%] vs 38 [46%]), and death

26 No deaths, serious adverse events (AEs), Grade 4 AEs or AEs leading

27 tients in the placebo group; the most common serious adverse events (affecting >/=2% of patients) wer

28 140 in the placebo group; the most frequent serious adverse events (affecting >/=2% of patients) wer

29 stive heart failure, or CVD death), and (ii) serious adverse events (hypotension, syncope, electrolyt

30 hose in the placebo group, or in the risk of serious adverse events (in 8.3% in the vaccine group and

31 endent factors associated with the number of serious adverse events (OR 3.07 [95% CI 1.75-5.38; p=0.0

32 Serious adverse events (regardless of relation to study

33 o significant difference in the incidence of serious adverse events (RR: 1.02; 95% CI: 0.94 to 1.09)

34 for IS contraindications were predefined and serious adverse events (SAEs) were reported to ethics co

35 tissue sarcoma group) had treatment-emergent serious adverse events (SAEs), five of whom had immune-r

36 re underpowered to identify risk factors for serious adverse events (SAEs), thereby limiting their in

37 days, and 3-, 6-, and 12-months for safety (serious adverse events [SAE]), and efficacy endpoints: e

38 nt difference between groups in the rates of serious adverse events and serious infections.

39 treatment costs, treatment-related risks of serious adverse events and subsequent costs, and quality

40 Mortality and overall serious adverse events at 90 days were not significantly

41 No other serious adverse events attributable to angiotensin II we

42 loss in children and is not associated with serious adverse events attributed to its use.

43 nce of large differences in risk of systemic serious adverse events between these two anti-VEGF drugs

44 Overall and serious adverse events did not differ between the flecai

45 The overall rate of serious adverse events did not differ between treatment

46 tic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly betw

47 Serious adverse events for all patients included anastom

48 y outcome as percentage of participants with serious adverse events in all participants who were inje

49 d, were febrile neutropenia (27 [17%] of 155 serious adverse events in patients who received doxorubi

50 who received doxorubicin and 15 [12%] of 130 serious adverse events in patients who received gemcitab

51 Treatment-emergent serious adverse events occurred in 103 (7%) women in the

52 Serious adverse events occurred in 11% of the patients w

53 A total of 38 serious adverse events occurred in 15 patients (5 events

54 Serious adverse events occurred in 15% of the patients i

55 Serious adverse events occurred in 19 patients (33%) in

56 Serious adverse events occurred in 2 patients in the IFN

57 Drug-related serious adverse events occurred in 28 (38%) of 74 patien

58 Five serious adverse events occurred in 4 cases (15%), includ

59 Serious adverse events occurred in 75 (19%) patients in

60 Eight serious adverse events occurred in each group.

61 Three serious adverse events occurred that were unrelated to t

62 Two unexpected serious adverse events occurred, both for the first pati

63 o episodes of serious hypoglycaemia or other serious adverse events occurred.

64 Serious adverse events occurring in 5% or more of patien

65 Serious adverse events occurring in more than 2% of pati

66 Serious adverse events occurring in more than two patien

67 lesterol and safety outcomes, either for all serious adverse events or any of the other nine prespeci

68 There were no serious adverse events or discontinuations due to advers

69 There was no significant excess of serious adverse events prespecified as being of special

70 se events, representing 111 (39%) of all 285 serious adverse events recorded, were febrile neutropeni

71 30672 treatment for 14 days was safe with no serious adverse events reported.

72 Serious adverse events such as infection, urinary retent

73 and no placebo recipients experienced fatal serious adverse events suspected to be study drug-relate

74 The most common serious adverse events that occurred through week 24 wer

75 The most common serious adverse events were anaemia (eight [4%]), upper

76 Overall adverse events and serious adverse events were balanced between the two gro

77 No vaccine-related serious adverse events were documented.

78 Serious adverse events were experienced by 35 (18%) pati

79 Thirteen serious adverse events were identified among recipients

80 Serious adverse events were more frequent the in G-CSF a

81 Serious adverse events were rare (6 patients) and were o

82 Serious adverse events were recorded in three (3%) patie

83 Four serious adverse events were reported during the conduct

84 Eight serious adverse events were reported during the course o

85 Serious adverse events were reported in 102 (25%) of 403

86 Serious adverse events were reported in 13 (13%) of 103

87 Treatment-related serious adverse events were reported in 133 (37%) patien

88 Serious adverse events were reported in 134 (23%) of 573

89 Serious adverse events were reported in 155 (49%) versus

90 Serious adverse events were reported in 20 (22%) patient

91 Serious adverse events were reported in 24% of the patie

92 Serious adverse events were reported in 56 (58%) eltromb

93 Serious adverse events were reported in 64 (22%) of 288

94 11 serious adverse events were reported in seven (25%) pati

95 0 (32%) of 156 in the placebo group, and 181 serious adverse events were reported in total, 95 (52%)

96 Three serious adverse events were reported, all in patients in

97 in severity, and no severe adverse events or serious adverse events were reported.

98 No serious adverse events were reported.

99 Treatment-related serious adverse events were similar between groups (13 [

100 Serious adverse events within 12 months after injection

101 s are the incidence of study product-related serious adverse events within 180 days, grade 3 solicite

102 idences of blood-product use, infection, and serious adverse events, as well as 28-day mortality, did

103 Central Africa because of the occurrence of serious adverse events, including death, in persons with

104 Seven (44%) of 16 patients had serious adverse events, most of which were related to th

105 There were no treatment-related serious adverse events, no treatment-related unsolicited

106 11 (8%) patients had serious adverse events, none of which were deemed relate

107 nuations occurred because of adverse events, serious adverse events, or deaths in patients who receiv

108 The three most common serious adverse events, representing 111 (39%) of all 28

109 Three serious adverse events-febrile neutropenia, intestinal p

110 relapsed and 2 discontinued treatment due to serious adverse events.

111 Study drugs were well tolerated with no serious adverse events.

112 and fall (n=6; 20%); four patients (13%) had serious adverse events.

113 f-care identification of persons at risk for serious adverse events.

114 s required discontinuation of therapy due to serious adverse events.

115 ences in the risk of death, cancer, or other serious adverse events.

116 t strategy, however, could be an increase in serious adverse events.

117 and PD-1 were associated with lowest risk of serious adverse events.

118 16 (2%) of 664 participants had serious adverse events.

119 icipants who had lower versus higher ARIs in serious adverse events.

120 Six (3%) patients had 11 serious adverse events: one (2%) patient in the placebo

121 30 days after surgery; delirium; mortality; serious adverse events; and neurocognition.

122 12 patients reported serious adverse events; haemolysis and pyrexia were the

123 Two (1%) of 166 patients had serious adverse events; neither were considered related

124 that hormone therapy use is associated with serious adverse health effects in postmenopausal women,

125 One unexpected, possibly related, serious adverse reaction that occurred 7 days after a 64

126 The most common serious adverse reaction was infection occurring in five

127 Serious adverse reactions necessitating hospitalisation

128 No serious adverse reactions were recorded and other safety

129 Serious AEs (SAEs) occurred infrequently.

130 Serious AEs (SAEs) were recorded through 6 months postva

131 A novel weed has recently emerged, causing serious agronomic damage in one of the most important ma

132 ological forecasting, but here we consider a serious alternative based on collective human judgment.

133 Epilepsy is a serious and common neurological disorder.

134 Obesity is a serious and growing worldwide health challenge.

135 luorescein angiography has shown potentially serious and long-term ocular effects that are present mo

136 12 months after the procedure, and rates of serious and minor adverse events within 30 days of the p

137 Pulmonary embolism (PE) is a serious and prevalent cause of vascular disease.

138 It is a common, serious, and often fatal condition among older patients.

139 here, along with open questions that require serious attention for full understanding of the molecula

140 Pressure ulcers are serious, avoidable, costly and common adverse outcomes o

141 augment the host immune response to prevent serious bacterial infections, and represent a significan

142 to the data from such studies can result in serious bias in testing experimental effects.

143 d the OPN system play important roles in the serious bone abnormalities associated with MDD.

144 Serious brain disorders, such as the Alzheimer's Disease

145 welve participants (2.0%) were found to have serious cardiorespiratory conditions that had been previ

146 venous thrombosis (DVT) remains a common and serious cardiovascular problem with both fatal and long-

147 hile water erosion is identified as the most serious cause of soil degradation globally, global patte

148 The development of such platforms faces serious challenges at both the technological level due t

149 ate that plant cells can respond flexibly to serious challenges of compromised MT-dependent MT nuclea

150 ve a responsibility to rebut and decry these serious challenges to human health and scientific integr

151 catheters that block urine flow and lead to serious clinical complications.

152 healthy individuals and a central aspect of serious clinical conditions, such as eating disorders.

153 esorption by osteoclasts (OCs) can result in serious clinical outcomes, including bone loss that may

154 elderly, had poor prognostic factors, or had serious comorbidities.

155 Stent thrombosis (ST) is a serious complication following coronary stenting.

156 ant lymphoproliferative disorder (PTLD) is a serious complication in organ transplant recipients and

157 Peritoneal fibrosis (PF) is a serious complication in various clinical settings, but t

158 Infection is a serious complication of cardiovascular-implantable elect

159 UND & AIMS: Hepatic encephalopathy (HE) is a serious complication of cirrhosis and is associated with

160 Acute chest syndrome (ACS) is a common, serious complication of sickle cell disease (SCD) and a

161 nation, surgical site infections (SSI) are a serious complication that can result in delayed wound he

162 or persistent infections are correlated with serious complications in humans, understanding these pro

163 tions, there was a higher rate of predefined serious complications in the elderly group (5 events vs.

164 Most serious complications led to hospitalization, and most G

165 The risk of serious complications was higher in the elderly group.

166 Four serious complications were evaluated: posterior capsule

167 No serious complications were observed.

168 There were no serious complications, such as lens subluxation or endop

169 es has lifesaving potential, but can lead to serious complications.

170 on and the lack of an approved vaccine raise serious concerns regarding preparedness to combat this e

171 quantify the global burden of this rare but serious condition.

172 s may offer another option for managing this serious condition.

173 sciences but light-induced side effects are serious confounding factors.

174 tworks extracted from the multiplex may have serious consequences in the characterization of the true

175 Plant pathogens cause serious crop losses worldwide.

176 20% (11/55) of BHFS survivors suffer from a serious delay of >/=6 months.

177 nisitic bacteria that are capable of causing serious diseases, mainly in immunocompromised individual

178 as a result of increased recognition of this serious disorder but more so because of the increased us

179 Anorexia nervosa (AN) is a serious eating disorder characterized by self-starvation

180 to most immersed solid surfaces, leading to serious economic and ecological consequences for the mar

181 Serious encephalopathy occurred in 3 patients (11%); 2 c

182 ed (FI)-RSV vaccine has been associated with serious enhanced respiratory disease (ERD).

183 a reliable passivating layer to survive the serious environmental corrosion during handling and cycl

184 , an organophosphate insecticide, has raised serious environmental health concerns since it is a pote

185 ess Phosphorus (P) in agriculture is causing serious environmental problems like eutrophication of la

186 haze events often occurred in China, causing serious environmental problems.

187 IVIg group) and 4 in the open IVIg phase had serious events.

188 did not cause irreversible loss of vision or serious eye damage.

189 item from each domain, the 10-point SaFETy (Serious fighting, Friend weapon carrying, community Envi

190 n enterohemorrhagic bacteria responsible for serious foodborne outbreaks that causes diarrhoea, fever

191 resistant bacterial pathogens have become a serious global human health threat, and conjugative plas

192 ity from fisheries is clearly among the most serious global threats for marine ecosystems, affecting

193 er clinical development for the treatment of serious Gram-negative infections.

194 ne seems to be associated with a low rate of serious harms, but no study evaluated risks of transport

195 Influenza is a serious hazard to human health that causes hundreds of t

196 us (HCV)-mediated chronic liver disease is a serious health problem around the world and often causes

197 bladder outlet obstruction continue to be a serious health problem.

198 contaminated vegetables and grains may pose serious health risks.

199 rages, and packaging, with the potential for serious health, as well as significant economic and soci

200 h levels of exposure, indicate a potentially serious human health burden from air pollution in the Ka

201 Staphylococcus aureus is a serious human pathogen with remarkable adaptive powers.

202 No episodes of serious hypoglycaemia or other serious adverse events oc

203 Ebola virus disease (EVD) is a serious illness with mortality rates of 20-90% in variou

204 improve the quality of life of children with serious illnesses and their families.

205 Non-human-derived PAbs can have serious immunoreactivity complications, and when "humani

206 The projected losses have serious implications for the hydropower, municipal and a

207 before neurological disease becomes overt or serious.IMPORTANCE The detection of highly compartmental

208 outpatient visits, and diagnoses were rarely serious in the ambulatory setting but potentially life t

209 Burkholderia species can cause serious infection in CF and themselves affect key oxidas

210 We found no evidence of increased odds of serious infection in comparisons of the different treatm

211 Serious infection occurred in 1.3% of the patients treat

212 The risk of serious infection should not be a key discriminator for

213 A total of 283 patients had a serious infection; the incidence rates with 95% confiden

214 We assessed the risk of serious infections for biologics used to treat psoriasis

215 is an opportunistic pathogen that can cause serious infections in immunocompromised individuals.

216 SSIs, particularly serious infections resulting in hospitalization or surgi

217 Three (2%) serious infections, all in patients in the ixekizumab ev

218 rsus without risk factors for development of serious infections, such as contact lens wearers (P = 0.

219 s in the rates of serious adverse events and serious infections.

220 s are available to treat patients with these serious infections.

221 d Beetle (ALB) Anoplophora glabripennis is a serious invasive forest pest in several countries includ

222 ctional, elastic SEIs that overcome the most serious limitations of spontaneously formed interphases

223 However, these platforms suffer from serious limitations, including small sample sizes.

224 s drugs, acyclovir and its derivatives, have serious limitations, such as low bioavailability and sev

225 However, democratic methods have serious limitations.

226 n women (heterogeneity P<0.001), but RRs for serious liver complications appeared higher in women (he

227 ae and is the single most important cause of serious lower respiratory tract infections in young chil

228 Glomerulonephritis is one of the most serious manifestations of systemic lupus erythematous (S

229 maternal mortality worldwide and may lead to serious maternal complications, including stroke, eclamp

230 geneous genomic population and may result in serious medical conditions.

231 es modern society, contributing to a host of serious medical problems.

232 ticipants were 359 diverse probationers with serious mental health problems and functional impairment

233 to improve quality of care for patients with serious mental illness and cardiovascular risk factors.

234 st as a site for therapeutic intervention in serious mental illness, yet we know very little about th

235 abstinence in outpatients with co-occurring serious mental illnesses.

236 e 2 diabetes(T2D) are the most prevalent and serious metabolic diseases affecting people worldwide.

237 2014, rates of death prior to discharge and serious morbidities decreased among the NICUs in this st

238 ted that approximately 100,000 people suffer serious morbidity and 10,000 people die each year from t

239 No significant difference was found in serious morbidity between HSHs and LSHs for bariatric or

240 Main outcome measures included serious morbidity, in-hospital mortality, intensive care

241 se in the incidence of a diverse spectrum of serious neurologic syndromes.

242 in the brain tissue of HIV patients without serious neurological disease is consistent with their em

243 due to its association with microcephaly and serious neurological disorders.

244 ts in the once daily group (one of which was serious; none led to treatment discontinuation) and 68 (

245 ensive arm, but there were no differences in serious nonhematological toxicities.

246 events were mild to moderate in severity; no serious ocular adverse events were reported.

247 Post-transplant tuberculosis (PTTB) is a serious opportunistic infection in renal graft recipient

248 Drugs treating serious or life-threatening conditions can receive US Fo

249 time to any adverse event (primary outcome); serious or nonserious events; partial and complete remis

250 there were no differences between groups in serious or other adverse events.

251 cal or mild disease, infection can result in serious outcomes, including acute respiratory distress s

252 is full of small migrant insects, among them serious pests (e.g. some species of aphid), but also man

253 oxic or antimicrobial agents for controlling serious plant pathogens.

254 Delirium is a common and serious postoperative complication.

255 genome data analysis to the cloud can raise serious privacy concerns.

256 ological contamination of nanomaterials is a serious problem hampering their widespread use in biomed

257 Given the serious problem of drug resistance and the adverse side

258 A common and serious problem with this therapy is the patient's immun

259 Serious problems in the experimental design and data int

260 There were no pericardial effusions, but serious procedure/device-related events occurred in 3 pa

261 Delirium is a common and serious psychiatric syndrome caused by an underlying med

262 ics and occasional pandemics, representing a serious public health concern.

263 volving illicit and prescription drugs are a serious public health issue.

264 Traumatic brain injury (TBI) is a serious public health problem, often with devastating co

265 Cancer is currently one of the world's most serious public health problems.

266 pollution, including black carbon, entails a serious public health risk because of its carcinogenic p

267 nem-resistant Enterobacteriaceae (CRE) are a serious public health threat.

268 t our overall approach of nanomedicine needs serious reevaluation.

269 elusive how leukemic cells could acquire the serious resistance against RUNX1-inhibition therapies an

270 is the causative agent of whooping cough, a serious respiratory infection causing hundreds of thousa

271 ge indicated that the predictive ability for serious respiratory morbidity increased from 34 weeks (A

272 , and 23% were other race/ethnicity), 88 had serious respiratory morbidity, 257 infants had neurosens

273 Serious respiratory morbidity, neurosensory impairment a

274 stability of photoelectrode materials impose serious restrictions on its advancement.

275 The quality of evidence is very low due to serious risk of bias and imprecision.

276 ed bleeding and pathological thrombosis pose serious risks to hospitalized patients.

277 n emerging pathogen causally associated with serious sequelae in fetuses, inducing fetal microcephaly

278 e Unit (ICU) patients and is associated with serious short- and long-term consequences, including re-

279 This article examines the serious shortcomings that characterize the current taxon

280 The most serious side effects were exacerbation of left ventricul

281 ic cleft lip with palate (NSCLP) is the most serious sub-phenotype of non-syndromic orofacial clefts

282 s due to the rapid industrialization poses a serious threat on the environment.

283 he extraction of tantalum and niobium pose a serious threat to human beings and the environment due t

284 ection by HRP2-based RDTs, would represent a serious threat to malaria elimination efforts.

285 g, acidification, and deoxygenation, poses a serious threat to marine organisms.

286 phere, from Africa via Asia, it has become a serious threat to pregnant women, causing microcephaly a

287 outbreak of Zika virus (ZIKV) has imposed a serious threat to public health.

288 borne pathogen Campylobacter is considered a serious threat to public health.

289 nly driving species to extinction, they pose serious threats to human health and wellbeing.

290 iruses cause inclusion body disease (IBD), a serious transmissible disease of snakes.

291 ide and 43 (10%) taking carbamazepine-CR had serious treatment-emergent adverse events, and 47 (11%)

292 36 (10%) of 370 patients had a serious treatment-related adverse event.

293 Six (11%) of 53 patients had a serious treatment-related adverse event: autoimmune diso

294 in the twice daily group (two of which were serious; two led to treatment discontinuation).

295 of gemfibrozil in warfarin users results in serious underanticoagulation.

296 children who develop this complication have serious underlying medical disorders.

297 s of current oncology clinical practice have serious, unmet health information technology needs.

298 was associated with greater adjusted odds of serious ventricular arrhythmias (OR, 31.8; 95% CI, 4.3-2

299 disorder that is progressive and may lead to serious visual impairment.

300 timicrobial-resistant (AMR) bacteria poses a serious worldwide health concern.